Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
15
07
2022
accepted:
23
11
2022
pubmed:
12
1
2023
medline:
27
1
2023
entrez:
11
1
2023
Statut:
ppublish
Résumé
In adults with type 2 diabetes, the benefits of fully closed-loop insulin delivery, which does not require meal bolusing, are unclear. In an open-label, single-center, randomized crossover study, 26 adults with type 2 diabetes (7 women and 19 men; (mean ± s.d.) age, 59 ± 11 years; baseline glycated hemoglobin (HbA1c), 75 ± 15 mmol mol
Identifiants
pubmed: 36631592
doi: 10.1038/s41591-022-02144-z
pii: 10.1038/s41591-022-02144-z
pmc: PMC9873557
doi:
Substances chimiques
Insulin
0
Blood Glucose
0
Hypoglycemic Agents
0
Glycated Hemoglobin
0
Banques de données
ClinicalTrials.gov
['NCT04701424']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
203-208Subventions
Organisme : Department of Health
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023. The Author(s).
Références
Chatterjee, S., Khunti, K. & Davies, M. J. Type 2 diabetes. Lancet 389, 2239–2251 (2017).
doi: 10.1016/S0140-6736(17)30058-2
International Diabetes Federation. International Diabetes Federation Diabetes Atlas, 9th edn (2019). https://diabetesatlas.org/atlas/ninth-edition/ (accessed August 2021).
Skyler, J. S. et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32, 187–192 (2009).
doi: 10.2337/dc08-9026
Nauck, M. A., Wefers, J. & Meier, J. J. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol. 9, 525–544 (2021).
doi: 10.1016/S2213-8587(21)00113-3
Cahn, A., Miccoli, R., Dardano, A. & Del Prato, S. New forms of insulin and insulin therapies for the treatment of type 2 diabetes. Lancet Diabetes Endocrinol. 3, 638–652 (2015).
doi: 10.1016/S2213-8587(15)00097-2
Heller, S. R., Peyrot, M., Oates, S. K. & Taylor, A. D. Hypoglycemia in patient with type 2 diabetes treated with insulin: it can happen. BMJ Open Diabetes Res. Care 8, e001194 (2020).
doi: 10.1136/bmjdrc-2020-001194
Boughton, C. K. & Hovorka, R. New closed-loop insulin systems. Diabetologia 64, 1007–1015 (2021).
doi: 10.1007/s00125-021-05391-w
Leelarathna, L. et al. Hybrid closed-loop therapy: where are we in 2021? Diabetes Obes. Metab. 23, 655–660 (2021).
doi: 10.1111/dom.14273
Forlenza, G. P. & Lal, R. A. Current status and emerging options for automated insulin delivery systems. Diabetes Technol. Ther. 24, 362–371 (2022).
doi: 10.1089/dia.2021.0514
Thabit, H. et al. Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial. Lancet Diabetes Endocrinol. 5, 117–124 (2017).
doi: 10.1016/S2213-8587(16)30280-7
Bally, L. et al. Closed-loop insulin delivery for glycemic control in noncritical care. N. Engl. J. Med. 379, 547–556 (2018).
doi: 10.1056/NEJMoa1805233
Boughton, C. K. et al. Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 7, 368–377 (2019).
doi: 10.1016/S2213-8587(19)30061-0
Boughton, C. K. et al. Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. Nat. Med. 27, 1471–1476 (2021).
doi: 10.1038/s41591-021-01453-z
Khunti, K., Ceriello, A., Cos, X. & De Block, C. Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta-analysis. Diabetes Res. Clin. Pract. 137, 137–148 (2018).
doi: 10.1016/j.diabres.2017.12.004
The International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 7, 385–396 (2019).
doi: 10.1016/S2213-8587(18)30315-2
Khunti, S., Khunti, K. & Seidu, S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther. Adv. Endocrinol. Metab. 10, 2042018819844694 (2019).
doi: 10.1177/2042018819844694
Polonsky, W. H., Fisher, L., Hessler, D. & Edelman, S. V. Investigating hypoglycemic confidence in type 1 and type 2 diabetes. Diabetes Technol. Ther. 19, 131–136 (2017).
doi: 10.1089/dia.2016.0366
Cox, D. J., Irvine, A., Gonder-Frederick, L., Nowacek, G. & Butterfield, J. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care 10, 617–621 (1987).
doi: 10.2337/diacare.10.5.617
Polonsky, W. H. et al. Assessment of diabetes-related distress. Diabetes Care 18, 754–760 (1995).
doi: 10.2337/diacare.18.6.754
JonesB. & KenwoodM. G. Design and Analysis of Cross-Over Trials, 3rd edn (CRC Press, 2014).
doi: 10.1201/b17537